M&A Deal Summary

CSL Acquires Wuhan Biological Products Research Institute

On June 13, 2017, CSL acquired life science company Wuhan Biological Products Research Institute from Humanwell Healthcare for 352M USD

Acquisition Highlights
  • This is CSL’s 2nd transaction in the Life Science sector.
  • This is CSL’s 2nd largest (disclosed) transaction.
  • This is CSL’s 1st transaction in China.

M&A Deal Summary
Date 2017-06-13
Target Wuhan Biological Products Research Institute
Sector Life Science
Buyer(s) CSL
Sellers(s) Humanwell Healthcare
Deal Type Divestiture
Deal Value 352M USD

Target

Wuhan Biological Products Research Institute

Wuhan, China
Wuhan Biological Products Research Institute Co. Ltd. develops, manufactures and commercialises plasma-derived products for the Chinese domestic market. This includes albumin, immunoglobulin (Ig) for IV injection, as well as several hyperimmune Ig products. The company also has an advanced pipeline of multiple coagulation factor products that it plans to launch in the coming years, including plasma-derived Factor VIII. In addition, Ruide owns four plasma collection centres and one manufacturing facility in Wuhan, Central China.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

CSL

Melobourne, Australia
Category Company
Founded 1916
Sector Life Science
Employees32,698
Revenue 14.7B USD (2024)
DESCRIPTION

CSL is a manufacturer and marketer of pharmaceutical and diagnostic products, cell culture media and human plasma fractions. CSL was founded in 1916 and is based in Melbourne, Australia.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 1 of 1
Country (China) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-06-02 Talecris Biotherapeutics Holdings Corp

Research Triangle Park, North Carolina, United States

Talecris Biotherapeutics Holdings Corp. is a pharmaceutical Development and Manufacturing company.

Sell -

Seller(S) 1

SELLER

Humanwell Healthcare

Wuhan, China
Category Company
Founded 1993
Sector Life Science
Employees17,676
Revenue 24.5B CNY (2023)
DESCRIPTION

Humanwell Healthcare is a fully integrated healthcare solution provider in Asia Pacific, North America, Europe and Africa. Founded in 1993 by a group of passionate college graduates, Humanwell has since transformed into a fully integrated healthcare solution provider. Humanwell has been active presence in over 10 countries and districts to date. Since its establishment, Humanwell has been endeavouring to bring safe and effective medicines to the world through the quality of its products and the integrity of its people. Humanwell Healthcare was founded in 1993 and is based in Wuhan, China.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (China) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-05-25 LifeStyles

Singapore, Singapore

LifeStyles is specialized in sexual wellness sector, possessing a broad product range. LifeStyles was founded in 1905 and is based in Singapore.

Buy $600M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-01 LifeStyles

Singapore, Singapore

LifeStyles is specialized in sexual wellness sector, possessing a broad product range. LifeStyles was founded in 1905 and is based in Singapore.

Sell -
Mergr

Product

Company

Legal